Balance Sheet Data
BioCryst Pharmaceuticals, Inc. (BCRX)
$8.35
-0.04 (-0.48%)
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
Total Cash | 104.47 | 136.23 | 300.37 | 507.60 | 424.31 | 5,304.76 | 17,606.84 | 58,438.23 | 193,960.27 | 643,766.73 |
---|---|---|---|---|---|---|---|---|---|---|
Total Cash (%) | ||||||||||
Account Receivables | 4.29 | 22.15 | 8.65 | 29.41 | 50.60 | 273.39 | 907.41 | 3,011.76 | 9,996.22 | 33,178.09 |
Account Receivables (%) | ||||||||||
Inventories | 1.65 | 3.90 | 1.42 | 12.55 | 21.62 | 71.77 | 238.21 | 790.64 | 2,624.17 | 8,709.80 |
Inventories (%) | ||||||||||
Accounts Payable | 7.77 | 13.99 | 18.71 | 27.81 | 14.36 | 349.33 | 1,159.45 | 3,848.31 | 12,772.78 | 42,393.67 |
Accounts Payable (%) | ||||||||||
Capital Expenditure | -0.37 | -0.34 | -0.51 | -2.38 | -1.35 | -13.26 | -44.02 | -146.09 | -484.88 | -1,609.35 |
Capital Expenditure (%) |
To support growth, companies need to keep investing in capital items – including property, plants and equipment.
To calculate this net investment,we take capital expenditure (found in the company’s statement of cash flows)
and subtract non-cash depreciation (found on the income statement).
Working capital refers to the cash a company needs for day-to-day operations.
The faster a company expands, the more cash it will need.
To calculate working capital, we take current assets and subtract current liabilities.
You can find both of these on a company’s balance sheet, which is published in its quarterly and annual financial statements.